PRX-03140

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
PRX-03140
PRX-03140.svg
Clinical data
ATC code
  • None
Identifiers
  • 4-hydroxy-7-isopropyl-6-oxo-N-[3-(1-piperidinyl)propyl]-6,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H27N3O3S
Molar mass377.50 g·mol−1
3D model (JSmol)
  • CC(C)N1C(=O)\C(=C(\O)c2ccsc12)C(=O)NCCCN3CCCCC3
  • InChI=1S/C19H27N3O3S/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21/h7,12-13,23H,3-6,8-11H2,1-2H3,(H,20,24)
  • Key:SCHKZZSVELPJKU-UHFFFAOYSA-N

PRX-03140 is a partial agonist (18% relative to 5-HT[1]) of the 5-HT4 receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease.[2]

Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts. In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc. (www.nanopharmaceutics.com) continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials.

References[edit]

  1. ^ Shen F, Smith JA, Chang R, et al. (2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. S2CID 43281377.
  2. ^ Shen, F (August 2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. S2CID 43281377.